Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5335436 | 0.84 | TLR7 (0.50) | ADORA2AADORA3ADORA1TLR8TLR7 | |
| SCHEMBL212373 | 0.84 | TLR8 (0.46) | ADORA2ATLR8TLR7POLB | |
| SCHEMBL211777 | 0.83 | POLB (0.42) | ADORA3ADORA1POLBCDK9DYRK1A | |
| SCHEMBL787142 | 0.80 | QTRT1 (0.51) | ADORA2AADORA3ADORA1TLR8TLR7 | |
| SCHEMBL18268482 | 0.80 | TLR7 (0.41) | ADORA2AADORA3ADORA1TLR8TLR7 | |
| SCHEMBL24414995 | 0.77 | TLR7 (0.42) | ADORA2AADORA3ADORA1TLR8TLR7 | |
| SCHEMBL30345730 | 0.77 | TLR7 (0.42) | ADORA2AADORA3ADORA1TLR8TLR7 | |
| SCHEMBL8600371 | 0.77 | TNKS2 (0.53) | ADORA2AADORA3ADORA1TLR8TLR7 | |
| SCHEMBL20968317 | 0.76 | PARP1 (0.41) | TLR8TLR7 | |
| SCHEMBL9036182 | 0.75 | TLR7 (0.52) | ADORA2AADORA3ADORA1TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948173-B1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-1948173-B1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2013-07-17 | — | — | EP | disclosed |
| US-8377957-B2 | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377957-B2 | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377957-B2 | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120071463-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-03-22 | — | — | US | disclosed |
| US-20120071463-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-03-22 | — | — | US | disclosed |
| US-20120071463-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-03-22 | — | — | US | disclosed |
| US-8088790-B2 | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088790-B2 | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088790-B2 | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090221556-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221556-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221556-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| EP-1948173-A2 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | Coley Pharmaceutical Group, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007056112-A2 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056112-A2 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221556-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | IFNG, IL2, IRF3 | ADORA2A 2291/4885ADORA3 2618/4885ADORA1 3300/4885 |
| US-20120071463-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | IFNG, IL2, IRF3 | ADORA2A 2291/4885ADORA3 2618/4885ADORA1 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.